PER-082-07已完成未知
DASATINIB IN SUBJECTS WITH CHRONIC MYELOID LEUKEMIA OR ACUTE LYMPHOBLASTIC LEUKEMIA WITH POSITIVE PHILADELPHIA CHROMOSOME EXPERIMENTING CLINICAL BENEFITS IN CURRENT START PROTOCOLS: LONG-TERM SECURITY AND EFFECTIVENESS ANALYSIS
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Written informed consent signed
- •Reference population (according to the previous START protocols) a) Patients previously treated in protocols CA180005, CA180006, CA180013, CA180015 or CA180017. b) Patients who obtained a clinical benefit with dasatinib or imatinib (study CA180017) according to the opinion of the researcher.
- •Age and sex. Men and women 18 years of age or older may participate. Fertile women should be using an adequate contraceptive method to avoid pregnancy throughout the study and for a minimum period of 1 month (4 weeks) before joining and a minimum period of 3 months (12 weeks) after the last dose of the product under investigation, in such a way as to minimize the possibility of pregnancy. The term fertile woman includes any woman who has had her menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or that is not postmenopausal (defined by amenorrhea for> 12 consecutive months; or women with hormone replacement therapy [HRT] with a documented level of follicle-stimulating hormone [FSH]> 35 mIU / ml). Even women who use oral contraceptives, other hormonal contraceptives (vaginal products, skin patches or implanted or injectable products) or mechanical products such as an intrauterine device or barrier methods (diaphragms, condoms, spermicides) to prevent pregnancy or to practice abstinence or those whose partners are sterile (eg, vasectomy) will be considered fertile. Fertile women should have a negative serum or urine test for pregnancy (minimum sensitivity of 25 IU / 1 or equivalent units of HCG) within 72 hours prior to the start of the investigational product.
排除标准
- •Fertile women who do not wish or can not use an acceptable method to avoid pregnancy during the entire study period and for a minimum period of one month (4 weeks) before joining and a minimum period of 3 months (12 weeks) after to the last dose of study medication.
- •Fertile women who use prohibited contraceptive methods (Not applicable for this study).
- •Women who are pregnant or breastfeeding.
- •Women with a positive pregnancy test at the time of enrollment or before receiving the product under investigation.
- •Sexually active fertile men whose sexual partners are fertile women who do not want or can not use an effective method to avoid pregnancy during the entire study period and for a minimum period of 3 months (12 weeks) after the conclusion of the medication of the study.
- •Serious uncontrolled medical conditions or active infections capable of altering the patient´s ability to receive protocol treatment.
- •Dementia or altered mental state that prevents understanding or interpreting informed consent.
- •Subjects who are taking medicines generally recognized for their risk of producing torsades de pointes (torsades de pointes), including, among others: ¨ quinidine, procainamide, disopyramide ¨ amiodarone, sotalol, ibutilide, dofetilide ¨ erythromycin, larithromycin ¨ chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, ziprasidone ¨ cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone,
- •halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine
- •Subjects taking medicinal products known to be potent inhibitors of CYP3A4 (ie, ketoconazole, ritonavir) or inducers (ie, rifampicin, efavirenz).
研究者
相似试验
招募中
2 期
Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission.JPRN-UMIN000008999Epidemiological and Clinical Research Information Network(ECRIN)50
已完成
2 期
Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission.chronic myeloid leukemiaJPRN-UMIN000005130Epidemiological and Clinical Research Information Network (ECRIN)50
进行中（未招募）
不适用
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome PositiveAcute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit onCurrent START or CA180039 Protocols: Long Term Safety and Efficacy Analysis.Revised Protocol Number 02 incorporating Administrative Letter 01 and Amendments 03 and 06 (v1.0, dated 24-Nov-2009)Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects.MedDRA version: 9.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaMedDRA version: 9.1Level: LLTClassification code 10034877Term: Philadelphia chromosome positiveMedDRA version: 9.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaEUCTR2007-003624-37-FIBristol Myers Squibb International Corporation313
进行中（未招募）
不适用
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome PositiveAcute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit onCurrent START Protocols: Long Term Safety and Efficacy Analysis.EUCTR2007-003624-37-IEBristol Myers Squibb International Corporation313
进行中（未招募）
不适用
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome PositiveAcute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit onCurrent START Protocols: Long Term Safety and Efficacy Analysis.Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects.MedDRA version: 9.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaMedDRA version: 9.1Level: LLTClassification code 10034877Term: Philadelphia chromosome positiveMedDRA version: 9.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaEUCTR2007-003624-37-HUBristol Myers Squibb International Corporation313